论文部分内容阅读
目的 :探讨干扰素联合大剂量胸腺肽对慢性乙型病毒性肝炎的治疗作用及机制。方法 :按诊断标准选择慢性乙型病毒性肝炎 1 0 0例 ,随机分为干扰素联合大剂量胸腺肽治疗组 (50例 )和干扰素对照组 (50例 ) ,观察比较两组患者的转氨酶及HBeAg、HBVDNA的变化 ,结果 :干扰素联合大剂量胸腺肽治疗组的转氨酶复常率 ,HBeAg及HBVDNA阴转率均明显高于对照组 (P <0 .0 5) ,结论 :大剂量胸腺肽能促进HBeAg的阴转 ,抑制HBV的复制 ,提高细胞免疫应答能力 ;干扰素联合大剂量胸腺肽治疗慢性乙型病毒性肝炎有较好的疗效 ,且使用安全
Objective: To investigate the therapeutic effect and mechanism of interferon combined with high-dose thymosin on chronic hepatitis B virus. Methods: One hundred and ten patients with chronic hepatitis B were selected according to diagnostic criteria and randomly divided into interferon plus high-dose thymosin (50 cases) and interferon control group (50 cases). The levels of serum transaminases, HBeAg and HBVDNA were observed. Results: The normal rate of aminotransferase, negative conversion rate of HBeAg and HBVDNA in interferon plus high-dose thymosin group were significantly higher than those in control group (P <0.05). Conclusion: High-dose thymosin can promote Negative HBeAg, inhibition of HBV replication and improve cellular immune response; interferon combined with high-dose thymosin in the treatment of chronic hepatitis B has a good effect, and the use of safe